Alcidion (ASX:ALC) share price dips 4% despite positive quarterly update

The healthcare technology company's shares are having a tough time on Tuesday

| More on:
a doctor with stethoscope around neck sits as a computer with head in hand, looking despondent.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Alcidion Group Ltd (ASX: ALC) share price is in negative territory today following the company's latest quarterly update.

During early afternoon trade, the healthcare technology company's shares are down 4.17% to 34.5 cents.

How did Alcidion perform in the first quarter of FY22?

In its release, Alcidion advised it has continued to build on FY21's momentum, leading into the new financial year. However, this has not been reflected in the Alcidion share price today.

For the 3 months ending 30 September (Q1 FY22), new contracted revenue surged to $17.2 million. This represents an increase of 17% over the prior corresponding period.

New contracted revenue grew $2.7 million in the quarter, defying what is historically known as the company's slowest quarter.

The bulk of the contracted revenue came from recurring revenue ($12.2 million), with non-recurring revenue taking up the remaining portion.

Cash receipts totalled $6.6 million, an improvement of 2.3% compared to this time last year.

On the other hand, operating cash outflow stood at $3.4 million. The outgoings reflected a full quarter of new hires in the second half of FY21 coupled with staff bonuses and GST payments.

At the end of September, Alcidion declared a strong cash balance of $21.5 million.

Notably, a further $3.1 million in revenue has been achieved in the current quarter (Q2 FY22) by 3 significant contracts.

The first relates to a 3-year deal valued at $630,000 with Queen's Hospital Burton in the United Kingdom. The agreement will see the deployment of ExtraMed's Inpatient Flow Manager (IPFM).

The second is also a 3-year contract with Sydney Local Health District, worth around $1.8 million in total. This will see the use of Miya Precision in supporting virtual care, initially of acute diverticulitis patients.

And lastly, the third agreement is a $640,000, 3-year extension for ExtraMed's IPFM Licence and support with Royal Derby Hospital in the UK.

It appears this news has not excited investors, with the Alcidion share price struggling to repeat its gains of yesterday.

Management commentary

Alcidion CEO Kate Quirke commented on the result:

Our pipeline continues to develop with several sizable opportunities now entering the contract negotiation stage which has provided a heightened optimism about the broader opportunity for Alcidion, particularly in the UK market. We are increasingly seeing the potential to cross and up-sell our products to existing customers.

We do however remain cognisant that COVID-19 continues to pose a challenge for healthcare providers worldwide resulting in longer lead times for contract completion.

Alcidion share price review

Although the Alcidion share price might be lower today, shareholders have recorded gains of almost 90% in 2021. When looking at the bigger picture, the last 12 months have seen its shares climb by almost 190%.

Alcidion has a market capitalisation of approximately $361.58 million, with more than 1.05 billion shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Alcidion Group Ltd. The Motley Fool Australia has recommended Alcidion Group Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »